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The evaluation of survivors of sudden cardiac death with 
serial etectrophysiologic studies invdves a lengthy and 
expensive hospitalization, enpetiaiiy when an automatic 
implantable wdiuverter.defibriliatur is ultimately nam. 
say. The cost efficacy of th$ conveutiunat appmach was 
therepore commwd with direct im~lantatbm of 8 cardim 
vwtwd&riliator after the first d&upbysiulugir study. 
Thirty-two survivors of sudden death who had inducible 
20.2 * 9.3 clays at a” nwrnge .zost of $4&9Rl * $31,6tw. 
Seven survivors ol sudden death had no inducible ventric. 
uiilr tachycardii during their initial riectrophysiologic 
studv and underwent direcl eardiuwier~de6briilator im- 
pin&lion. Their avoru~ length of huspttaittttou was 
12.6 zt 6.2 days at an average cust of $40,406 f $3,500. 
It is mnciud<.d that automatic impinntabte cardiuvarIw 
defibrtltator inmlantation as an early iutervsntii b not 
morec&iy andbdwd nay becust.&ive compared wtth 
lherapy guided by ariai eiectmpbysiolugic Wbtg. As 
anlitacbycardta devices become mure versatile, luug lived 
and easier to implant, earlier hupiantatian is likely tu 
cornpro wen marr favorably with drug therapy. 
(I Am Coil Cardi~ 1990;16:125S-63) 
ventricukr tachycardia during their initiai eiatruphysio- 
logic study undewent wriai drug trials. At discbar@ 12 
(37%) were taktne an anliarrhvthmtc dme round tu we- 
vent ~ducliou of v&rtcular tac’hycardia au> 20 undo&M 
enrdioverter.de6briilator imullantatiuu atIer srriai drue trt. 
Introduction of the automatic implantable cardioverter- 
defibrillator in antiurrhythmic therapy raises many important 
issues. Among them is the relative cost of this highly 
effective form d therapy in the management of patients with 
life-threatening ventricular tachyarrhythmias. The cardio- 
verter-defibrillator has clearly demonstrated its dramatic 
impact on sudden death mortality in a very high risk group of 
patients (l-4). It is an expensive intwention, however, and 
usually follows an already lengthy and expensive hospital- 
ization. The indication for device implantation in the major- 
ity of patients is drug-refractory ventricular tachycardia or 
ventricular fibrillation documented by serial drug trials and 
electrophysiologic studies (i-4). Although electiophyaiolog- 
ically guided therapy appears to be an improvement over 
noninvasive management of survivors of sudden death (j-7-7), 
the overall success of drug therapy for life-threatening 
arrhythmias has been somewhat disappointing. Against this 
background, the cardioverter-defibrillator data appear even 
more dramatic. Furthermore, it is likely that future devices 
will be even more attractive in terms ofease ofimplantation, 
size, sophistication and versatility. 
We sought to examine the per patient cost and length of 
hospitalization of conventional electrophysiologically guided 
therapy in wh’:h cardiovener-defibrillatore are reserved for 
drug-refractory patients compared with the per patient cost 
of direct device implantation ufterthe first episode of sudden 
cardiac death or life-threatening sustained ventricular tachv- 
wdia. 
Methods 
Study patients. The records of all patients referred to the 
Cardiac Arrhythmia Center between July 1985 and July 1988 
fur the initial evaluation of aborted sudden cardiac death or 
of life-threatening sustained ventricular tachycardia were 
reviewed. Patients were considered eligible for inclusion in 
the study if they met the following criteria: I) no prior 
evaluation for aborted sudden cardiac death or sustained 
ventricular tachycardia; 21 no ~wocnw of acute myocardv;d 
infarction, proarrhythmic response 1~1 an anlixrhyrhmic 
medication or metabolic disturbance at the time of the event. 
3) no contraindication to the surgery required for cardlo- 
verter-deiibtilltttor implantation. and 4) no mdicauon for 
coronary artery bypass surgery or left ventricular sncurys- 
llX.Ztomy. 
The 39 potimts included in rhr rrtrdv were rlwr sah- 
gronped rrccording to thr rewlls of lhek i&d ek rruph,w 
iologic study. The seven patw~ts (Group I) who had no 
inducible ventricular tachycardia or fibrillation at this bare- 
line study in the absence of antiarrhythmic drugs underwent 
implantation of a cardioverter-deUbrillator. The 32 patient, 
(Group II) who had inducible ventricular tachwxdn or 
fibrillation on their initial electrophysiologic study went on 
to further electrophysiologically guided therapy 
Data regarding the number of antiarrhythmic drug, and 
electrophysiologic studies each Qatienl encountered as well 
as the ultimate therapeutic outcome were obtained from the 
Cardiac Arrhythmia Center computerized data base. The 
number of antiarrhythmic drugs recorded includes a!l zpcot> 
available in an oral form that ;hs patient received durrng tbc 
current hospitalization for treatment of ventriculx arrhyth- 
mia. Any drugs previously taken were not included. Data on 
the length of slay and cost of hospitalization for all patients 
were obtained from the hospital billing departmeot and were 
calculated from the date of the baseline electrophysmlogic 
study until the date of discharge. The “cost of hospntalira- 
tian” represents the total charges billed to the patient during 
that period. 
ElPelrophysic4ogic shtdy. All patients underwent n base- 
line eleetrophysiolagic study without antiarrhythmic agents 
if possible. AAer informed consent was obtained. electro- 
physiologic testing was carried oat with the patient in the 
fasting state, using a small dose of oral diaepam premedi- 
cation if necessary. Two quadripolar electmde catheters 
with I cm interelectrode distance were used. Measuremenrr 
ofsinus node recovery time, atrioventricular node refractory 
period and catduction curve. pmgrammed atrial Stimulation 
and atrial burst pacing were carried ottt at the time of the 
initial electrophysiologic study in all patients. Programmed 
ventricular stimulation was then performed. The distal pair 
of electrodes of the ventricular catheter was used for bipolar 
right ventricular stimulation with a constant current Qro- 
gmmmable stimulator (Bloom Associates). Ventricular stim- 
ulation was carried oat first at the right ventricular apex 
and then if necessary at the right ventricular outflow war! 
and at a second right ventricular apical site. If sustained 
monomorphi:: ventricular tachycardin was not induced from 
the right ventricle, left vmtriculw stimulation was per- 
formed. 
The stimulation protocol employed three basic drive 
cycle lengths (6&l. 5UU and 45U ms). with up to three 
extmstimoli. delivered at twice diastolic threshold (54 mA) 
u ith .L p&e aldth of I ms. At each site. after determination 
ot’k r,enrncular effective refractory period. the fir%; cx~ra- 
i:lmular ~n~crval LS,S,l was xl at SU ms greater than the 
ventrulrlr effectwe refractory period. wth the mmal S,S, 
inlrrul wt dt twice S,& The S, was then rhoncned~in 
IO on incremcntr until S, became rcfmctorv: S, was tbcn 
bhoricncd by 10 ms and tbts sequence was r&&d until S2 
becum relrociory. The came promco, was then fo,,owed 
with the add&n of&. 
Antiorrhythmk drug therapy. The choice of antiarrhyth- 
ms therapy after each eiectrophyvolagic rtudy involved 
conGderatton of the patient’s ventricular Function, any 
Known drug ii~.olemoce and other Factors. In general. all 
patients received at least one class IA ageent. one class IC 
agent and one clzss IB agent alone or in combmation with a 
class IA or IC agent. Two ddferent agents from the same 
C!BSX kerr rued separately in patientr who were intolerant to 
one member of the class or in whom a partial response WBS 
thought to be present. A pstient who “failed” this seqocncc 
uf drug therapy on the basis of indwble ventricular tachy- 
cardn at ekcrrophysiologic study. drug intolerance or spon- 
taneow ventricular tachycardia was considered IO have a 
drug-refractory arrhythmia and underwent cardioverter- 
defibrillator implantation. 
Surgical procedure. The surgical approach employed for 
cardioverter-defibrillator implantation was a left anterior 
thoracotomy or subxiphoid incision. Two patch leads were 
used for the delibnllating leads in the majority of patients; 
the renrmg leads were endwardial or epicardial. The de- 
fibrdlation threshold was determined by inducing ventricular 
fibrillation with altemaing current and using an external 
cardiovertrr-defibrillator capable of delivering energies be- 
tween I nod 40 J. A threshold of <I5 J wan achieved in all 
patients. After connection of leads to the cardioverter- 
dcfibrdlator pulse generator. arrhythmia induction was re- 
peated to document appropriate sensing and termination of 
the arrhythmia by the device. Postoperatively, all patients 
were monitored for at least 24 h in an intensive care unit. 
Hospital discharge was generally on the 5th postoperative 
day if recovery was uneven!ful. A predischarge electrophys- 
iologic study was not routinely performed. 
Statistical aoalysb. The dara are reported as mean values 
-f SD and were analyzed by the unpaired. twc-tailed Stu- 
dent’s I ted. A Q value 5U.US was considered statisticall? 
significant. 
Results 
Clinical features. The entire study group consisted of 39 
patients (Table I). Seven patients (Group 1) underwent direct 
implantation of a cardiovener-defibrillator after their initial 
electraphysiologic study because ofthe absence ofinducible 
or spontaneous ventricular tachycardia to guide drug ther- 
apy; there were four men and three women with an average 
age of 46.1 years. At initial prexntation five had had 
ventriculat fibrillation and two had had ventricular tachycar- 
dia. The underlying heart disease was long QT syndrome in 
two patients, dilated cardiomyopathy in two, hypertmphic 
cardiomyopathy in one, mitral valve prolapse in one and no 
identifiable structural heart disease in one. 
The remainins 32 patients fGmp II) were found to be 
eligible for electmphysiologicaily guided therapy and under- 
went serial drug testing as outlined in the protocol. Twenty- 
six of these patient: had had ventricular tachycardia and 6 
had had ventricular fibrillation at initial presentation; 30 
were men and 2 were women with an average age of 61.3 
years. The underlying heart disease was coronary artery 
disease in 27 patients, dilated cardiomyopathy in 3 and 
vaivular heart disease in 2. Twentv-two of the 27 oatients 
with coronary artery disease had. had documetttdd prior 
myacardial infarction. Twenty-three Group II patients were 
not taking any antiarrhythmic drugs at the time they had a 
baseline electrophysiologic study performed. Nine Group II 
patients were taking an antiarrhythmic dtug at the time of 
their initial study, live because of recurrent destabilizing 
ventricular tachycardia and four at the discretion of the 
referring cardiologist. 
Treatment protocol. In I2 (37%) of the 32 Group II 
patients, the tachyamhythmia was rendered noninducible at 
electrophysiologic study and they were receiving antiar- 
rhythmic drug therapy alone at discharge without cardio- 
verter-defibrillatory &plantation (GmupUA). The remain- 
ing 20 Grout, 11 Datients (GIOUP 119) continued to have 
inducible ventricular tachycardia during serial electrophysi- 
ologic study and underwent cardioverter-deRhriUator im- 
plantation. Group 116 uadetwent more electrophysiologic 
studies than did Group IIA and received more antiarrhyth- 
mic drugs, although these aifferences did not achieve statis- 
tical significance. By study design. Group 1 patients had 
fewer electrophysiologic studies and received fewer an&x- 
rhythmic drugs during their hospitalization than did Group II 
patients. 
Length and cost of hospitalization (Table 2). Group 1 
patients (direct AICD implantation) had an average hospital 
stay of 12.6 2 6.2 days compared with 20.2 + 9.3 days for 
Table 2. Hospital Stay and Costs in the Patient Groups 
Group II (electrophysiologically guided therapy) (p = 0.0541 
calculated from the date of the tint electrophy5iol”gs crudy. 
The length of hospitalization for Group I patieats was similar 
to that of Group IIA (drug therapy) (12.0 r 6.2 days. p = 
NSF but significantly shorter than that of Group IIB (device 
implanlation after senal testmglt26.3 2 5.8 days. p < o.Wt). 
The c”st of hospitatizarian was $40.400 * $8.300 for 
Group 1. including the ~“$1 of the cardiovener-defibnllator 
The c”st of hosoitalization for Grow II ar a whcle was 
$48,900 + $31.6& tp = NS compareh with Group 1). The 
cost for Groom IIA was $17.200 2 $9.9.5tX sienificantlv less 
than that for &oup I (p 4 0.001). while thst”f”r Group 118 
was $73.400 2 $17.000. significantly more than that for 
Group I (P < 0.001). 
Although there was no significant cost difference between 
Grow I and Crow II as a whole. the ranee ofcosts ($27.600 
to $S2,400 for Group I versus $4.880 to SI 16.200 for Group 
II) suggests a trend toward lower and more uniform costs for 
Group 1. 
P&e”t follow.up. There n’ere nodeaths among the seven 
Grow 1 patients, with follow-uo ranaine from I? to 30 
mootis. Three patients experie&d at I& one defibrillator 
discharge, none of which required hospitalization. One pa- 
tient has had defibrillator generator replacement. 
Eleven of the 20 Group IIB patienti experienced at least 
one defibrillator dircharw. with follow-uo raneitte from I2 to 
30 months. Four pat& required hospital&ion for 
changes in the empiric aotiarrhythmic regimen after multiple 
appropriate defibrillator discharges. None of the Group 116 
patients have yet undergone defibrillator genentor replace. 
ment. There was one death in Group 119 as the result of a 
cerebrovascular accident. 
There were two deaths in Group HA. one a sudden 
cardiac death II months after discharge and the other of 
unknown cwse. Six patients are known to be without 
recurrences of ventric&r tachycardia “r Gbrillation and o” 
change in an&rhythmic therapy. with follow-up ranging 
from I2 to 30 months. Two patients required hospitalization 
for recurrent sustained ventricular tachycardia. Follow-up 
information is not available on the remaining two patients in 
Group HA. 
Discussion 
The automatic implantable cardioverter-defibrillator has 
been proved a highly e6ective treatment for the prevention 
of recurrent sudden cardiac death (l-4). It is also a very 
exc-ensive device and is usually implanted after a lone 
hospitalization. particularly when se&l electrophysiologxc 
studies have been used in an attempt :c iden:ify elective 
antiarrhythmic drug therapy. Our data suggest that early 
implantation of a cardioverter-defibnllalor in all patients 
with aborted sudden cardiac death would result in a shorter 
hospital stay at comparable or lower cost compared with 
ionwmionai aerial electr”phyr;i”l”gically guided therapy in 
which device implantation is reserved for only “drug- 
refractory” patxms. 
Cost etXcacy of antiarrhythmic therapy. Our data demon- 
strate rhat electrophysiolagiczily guided therapy results in a 
sigmficamiy Fhoner and less expensive hospitalization for 
rhe 37% of pauents far whom a successful antiamhylhmic 
drug is sdentified compared with the hospitalization required 
for “direct” cardiovener-defibrillator implantation. in con- 
trast. the cost and length of hospttabzation are signiftcanrly 
greater for the 63% of patients who undergo serial electro- 
physiologic srudy followed by cardioverter-defibrillator im- 
$&io~ compared with thbse of direct device implanta- 
11”“. 
The iawe of cost eilicacy is particularly pertinent in the 
management of patients with life-threatening ventricular 
arrhythmias because long hospitalizations and expensive 
interventions are commonplace. The evolution of electro- 
phyriologtcally guided therapy has been justified by its high 
predictive value and the reduction in recurrent events com- 
pared with rherapy guided by noninvasive end points (5-7). 
Although electrophysiologically guided therapy is initially 
more expensive. the reduction in readmissions for recurrent 
arrhythmias makes the overall cost comoarahle with that of 
efec;rocordiographically guided therapy. (8). However. the 
selection of antiarrhythmic therapy by serial electrophysio- 
logic testing is a time-consuming process with somewhat 
diminishing returns (9). Although etectrophysiologically 
guided therapy repreaems a significant advance. drug ther- 
apy in general still falls far short of a perfect solution for 
patients wit!) life-threatening ventricular dnhythmms. 
Current iudieatiins for Ihe atttomatiz deEb~l~a~o~. The 
automatic implantable cardiovener-defibrillator is part of a 
trend toward more aggrrssive therapy for this t$h risk 
group r7f patients. Currently. the indication far device im- 
&niatio~ in the major& of patients is drug-refractory 
ventricular tachwardia or fibrillation demonstrated by serial 
electr”physiolo& studies (Z.?i. The small group of patientr 
who receive a cardiove~er-defibrillator as the initial therapy 
are those who have presumed false negative electrophysirr 
logic studies-often those with long QT syndrome, cardio- 
myopathy or no identifmble structural heart disease. How- 
ever. as the “era of devises” advances rapidly toward 
systems that do not require a thoracotomy for implantation 
and that have programmable amitachycardia pacmg capabil- 
ity. it seems bkely that antitachycardia devices will Secome 
a more attractive option earlier in the management strategy. 
Thus. we believe that it is appmptiale to begin comparing 
the cost of device implantation as the initial intervention 
with that of the currem stmtepy of e!ectrophysiologically 
guided !herapy. 
The present study. The patients selected for this retro- 
Fpective study are survivors of sudden cardiac death or 
sustained ventricular tachycwdia who have not had prior 
invasive evaluation. Patients with recurrent aborted sudden in this study. Currently. the implanted generator must be 
cardiac death on antiarrhythmic therapy were excluded to replaced on average every 2 to 5 years, which adds consid- 
avoid preselection of patients more likely to have drug- erabty to the long-term cost. Conversely, patients generally 
refractory arrhythmias. Nevertheless. 63% of the patients do not need to be hospitalized after a defibrillator discharge, 
who were eligible for electrophysiologically guided therapy whereas recurrent venlricular lachycardia or fibrillalion in 
did ultimately prove to have drug-refractory arrhythmia and patients without a defibrillator frequently results in lengthy 
underwent cardiovener-defibr;llator imolantation. This is in and exoensive hoaoitalizations. Furthermore. it is often 
keeping with other studies (10-12) exarkng the success of 
electrophyaiologic testing in identifying a successful drug 
regimen. It is possible that furtherelectrophysiologic testing 
would have yielded a successful drug regimen for some of 
the patients who received a cardioverter.defihrillatar be- 
cause ewy possible drug combination was not tested in 
every patient. There is evidence, however. that the addi- 
tional yield becomes progressively smaller and the risk of 
complications higher with further serial studies (9). Thus, it 
is likely that more electrophysiologic studies to test addi- 
tional drug combinations would have increased the length 
and cost of hospitalization still further in Group 11. and the 
direct implantation approach would have then compared 
even more favorably. 
suggest that the response to intravenous procainamide dur- 
ing the initial electrophysiologic study is useful in selecting 
Thcrc is no general consensus as to how many drugs and 
which particular agents should be employed in the course of 
serial electrophysiologic studies. The present study. utilizing 
up to four drugs, including at least one from each subgroup 
of class I agents, is a common approach. Recent data (13) 
possibl; to make &nges in antiarrhythmic therapy an an 
outpatient basis in patients with an implanted defibrillator, 
whereas patients without the device might require hospital- 
ization. Thus. it is not inherently obvious whether the 
cardioverter-defibrillator will increase or decrease long-term 
costs. 
more acceptable as an earlier intervention. Implantation of a 
device without the need for thoracotomy may be less costly 
Future indications Ibr the atiomatic defibrillator. Direct 
implantation of a cardioverrer-defibrillator is not generally 
considered appropriw at this time for the majority of 
survivors of sudden death for a number of reasons: I) the 
cardioverter-defibrillator is a bulky device with a limited 
battery life span; 2) thoracotomy or at least a suhxiphoid 
approach is required for implantation; and 3) frequent device 
discharges in paticnts with frequent ventricular tachycardia 
would be unacceptable for the patient and would rapidly 
deplete the battery. However. these limitations are likely to 
be overcome in future antitachycardia devices. In particular, 
devices capable of programmable overdrive pacing for ven- 
tricular tachycrrdia with back-up defibrillation will be much 
patients for whom a successful drug regimen can be identi- and associated with less morbidity. It .rem&s to be seen 
fied. This might allow more rational selection of patients for whether antirachycardia devices will result in fewer rehos- 
serial drug testing while maintaining cost efficacy. Further pitalizations for recurrent ventricular tachycardia. 
studies are needed to define the ideal approach in terms of Conclusions. These data suggest hat implantation of the 
both outcome and cost. 
Study limitatiknts. There are several limitations inherent 
in this study. It is a retrospective study and the choice of 
antiarrhythmic agents was individualized and not predesig- 
nated. Nevertheless, the results in terms of identifying a 
successful drug regimen are similar to those of other studies. 
The patients in Group 1, used for comparing the cost and 
length of hospitalization for early cardiovener-defibrillator 
implantation, were on average younger than those in Group 
II and did not have coronary artery disease. These factors 
may have contributed to their shorter hospitalization period. 
currently available automatic implantabie cardioverter- 
defibrillatorr as an early intervention does not necessitate 
excessive cost and indeed may he cost-effective compared 
with conventional serial electrophysiologically guided ther- 
apy. It is likely that the more versatile antitachycardia 
devices being developed will be osed more widely and earlier 
in the trea ment of patients with life-threatening ventricular 
arrhythmias. 
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significantly underestimating length and cost of haspitaliza- 
lion. Furthermore. none of the Group II patients who 
underwent cardiovelter-defibrillator implantation after serial 
electrophysiologic testing had postoperative myocardial in- 
farction or congestive heart failure rest ting in prolongation 
of the hospital stay. 
The long-term cost of treating ventricular tachycardia 
with or without a cardioverter-defibrillator is not addressed 

